iRhythm Technologies to Present at the Canaccord Genuity 42nd Annual Growth Conference
iRhythm Technologies (NASDAQ:IRTC) has announced its participation in the Canaccord Genuity 42nd Annual Growth Stock Conference on August 11, 2022, at 12:00 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Technologies (NASDAQ:IRTC) has announced its participation in the Canaccord Genuity 42nd Annual Growth Stock Conference on August 11, 2022, at 12:00 p.m. Eastern Time. The company, known for its innovative cardiac care solutions, will provide a live and archived webcast of the presentation on its website. iRhythm specializes in diagnosing cardiac arrhythmias through wearable biosensor devices and advanced data analytics, aiming to enhance patient management through improved arrhythmia detection.
Details
News Market Reaction – IRTC
The recorded move for IRTC in the trading session of this news was -2.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, July 28, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming Canaccord Genuity 42nd Annual Growth Stock Conference.
iRhythm’s management is scheduled to present on Thursday, August 11, 2022, at 12:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.
Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
stephanie.zhadkevich@irhythmtech.com
iRhythm Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.